Quadrivalent HPV vaccine may be effective in young men

Source: www.medscape.org Author: Laurie Barclay, MD; Charles P. Vega, MD Quadrivalent human papillomavirus (HPV) vaccine may prevent infection with HPV types 6, 11, 16, and 18 and the development of related external genital lesions in young men 16 to 26 years old, according to the results of a randomized, placebo-controlled, double-blind trial reported in the February 3 issue of the New England Journal of Medicine. "Infection with ...HPV and diseases caused by HPV are common in boys and men," write Anna R. Giuliano, PhD, from the Risk Assessment, Detection, and Intervention Program, H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and colleagues. "We report on the safety of a quadrivalent vaccine (active against HPV types 6, 11, 16, and 18) and on its efficacy in preventing the development of external genital lesions and anogenital HPV infection in boys and men." The study sample consisted of 4065 healthy boys and men, aged 16 to 26 years, enrolled from 18 countries. The primary efficacy goal was to demonstrate that use of the quadrivalent HPV vaccine was associated with a lower incidence of external genital lesions related to HPV-6, 11, 16, or 18. The investigators used a per-protocol population, in which participants received all 3 vaccinations and had tested negative for relevant HPV types at enrollment, and an intent-to-treat population, in which participants received vaccine or placebo, regardless of baseline HPV status. In the intent-to-treat population, there were 36 external genital lesions in the vaccine group and 89 in the [...]

2011-02-15T13:47:01-07:00February, 2011|Oral Cancer News|

Dermatologist discusses advantages of vaccines that prevent human papillomavirus and herpes zoster

Source: www.prnewswire.com Author: public release Vaccines have a long history of successfully preventing disease and, in effect, improving the lives of countless Americans. Now, two serious diseases – human papillomavirus (HPV) and herpes zoster – could become a thing of the past as people better understand the safety and efficacy of vaccines to prevent these serious viral infections in specific populations. At the American Academy of Dermatology's Summer Academy Meeting 2010 in Chicago, dermatologist Jeffrey M. Weinberg, MD, FAAD, associate clinical professor of dermatology at Columbia University College of Physicians and Surgeons in New York City, highlighted the significant benefits associated with these two new vaccines. HPV Vaccine Protects Girls and Boys HPV is a group of viruses commonly linked to the sexually transmitted diseases known as genital HPV infection, which have long been associated with the development of cervical cancer, a life-threatening cancer. According to the American Cancer Society's 2010 estimates, approximately 4,210 women will die from cervical cancer in the United States. In 2006, a breakthrough vaccine was approved by the FDA for the prevention of HPV types 6, 11, 16 and 18. HPV types 6 and 11 are responsible for more than 90 percent of all cases of genital warts, and HPV types 16 and 18 cause 70 percent of all cervical cancers. Although the vaccine is specifically approved for use in females 9 to 26 years of age, Dr. Weinberg acknowledged that many people are still reluctant to get the vaccination due to a lack of [...]

Comparing the HPV vaccines

Source: www.hemonctoday.com Author: Debbie Blamble, PharmD, BCOP HPVs are double-stranded DNA viruses that affect epithelial cells. More than 100 strains of HPV have been detected. Approximately 40 strains are known to infect genital mucosa, of which about 15 strains are known to cause cancer. HPV types 16 and 18 are the most common cancer-causing strains, leading to about 70% of all cervical cancer cases worldwide. HPV types 6 and 11 are associated with about 90% of all cases of genital warts. Cervical intraepithelial neoplasia is an abnormality of the cervical epithelium associated with HPV infection and is thought to be a precursor to cervical cancer. CIN is classified into three grades: 1, 2, 3. With CIN-1, mild dysplasia is present and affects only the lowest third of the cervical epithelium; 70% to 90% of CIN-1 lesions undergo spontaneous regression. CIN-2 and CIN-3 show moderate to severe dysplasia and affect the lowest two-thirds to full thickness of the cervical epithelium, respectively. More than half of CIN-2 and CIN-3 cases are estimated to persist or progress to squamous cell cancer. Persistent HPV infection may also lead to cervical adenocarcinoma in situ. In the United States, screening with the Pap test identifies these precancerous lesions and has led to a decrease in the rates of cervical cancer. These precancerous lesions may develop less than five years after HPV infection. HPV infection HPV infection is most frequently acquired through sexual contact. It is estimated that more than 80% of men and women in the [...]

Go to Top